Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,830 GBX | -0.41% |
|
+1.09% | +2.28% |
Jun. 24 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
Jun. 20 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.28% | 5.29B | |
+63.05% | 856B | |
+39.22% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+5.11% | 234B | |
+16.31% | 226B | |
+14.63% | 177B | |
+1.08% | 165B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Transcript : Hikma Pharmaceuticals PLC Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 09